Abstract
Despite recent advances in treatment, multiple myeloma (MM) remains an incurable malignancy. By using in vitro, ex vivo and in vivo approaches, we have identified here that lipid rafts constitute a new target in MM. We have found that the phospholipid ether edelfosine targets and accumulates in MM cell membrane rafts, inducing apoptosis through co-clustering of rafts and death receptors. Raft disruption by cholesterol depletion inhibited drug uptake by tumor cells as well as cell killing. Cholesterol replenishment restored MM cell ability to take up edelfosine and to undergo drug-induced apoptosis. Ceramide addition displaced cholesterol from rafts, and inhibited edelfosine-induced apoptosis. In an MM animal model, edelfosine oral administration showed a potent in vivo antimyeloma activity, and the drug accumulated preferentially and dramatically in the tumor. A decrease in tumor cell cholesterol, a major raft component, inhibited the in vivo antimyeloma action of edelfosine and reduced drug uptake by the tumor. The results reported here provide the proof-of-principle and rationale for further clinical evaluation of edelfosine and for this raft-targeted therapy to improve patient outcome in MM. Our data reveal cholesterol-containing lipid rafts as a novel and efficient therapeutic target in MM, opening a new avenue in cancer treatment.
Similar content being viewed by others
References
Auer J, Berent R, Weber T, Eber B . (2002). Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr Med Chem 9: 1831–1850.
Ausili A, Torrecillas A, Aranda FJ, Mollinedo F, Gajate C, Corbalan-Garcia S et al. (2008). Edelfosine is incorporated into rafts and alters their organization. J Phys Chem B 112: 11643–11654.
Barnes K, Ingram JC, Bennett MD, Stewart GW, Baldwin SA . (2004). Methyl-beta-cyclodextrin stimulates glucose uptake in Clone 9 cells: a possible role for lipid rafts. Biochem J 378: 343–351.
Blanco-Prieto MJ, Campanero MA, Mollinedo F . (2004). Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography-electrospray mass spectrometry: application to cell uptake studies and characterization of drug delivery systems. J Chromatogr B Analyt Technol Biomed Life Sci 810: 85–92.
Busto JV, del Canto-Jañez E, Goñi FM, Mollinedo F, Alonso A . (2008). Combination of the anti-tumour cell ether lipid edelfosine with sterols abolishes haemolytic side effects of the drug. J Chem Biol 1: 89–94.
Cheng PC, Dykstra ML, Mitchell RN, Pierce SK . (1999). A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med 190: 1549–1560.
Christian AE, Haynes MP, Phillips MC, Rothblat GH . (1997). Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res 38: 2264–2272.
de Mendoza AE, Campanero MA, de la Iglesia-Vicente J, Gajate C, Mollinedo F, Blanco-Prieto MJ . (2009). Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin Cancer Res 15: 858–864.
Dessi S, Batetta B, Pulisci D, Spano O, Anchisi C, Tessitore L et al. (1994). Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer. Cancer 73: 253–258.
Dimberg LY, Dimberg AI, Ivarsson K, Stromberg T, Osterborg A, Nilsson K et al. (2005). Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood 106: 1346–1354.
Elahi MM, Cagampang FR, Anthony FW, Curzen N, Ohri SK, Hanson MA . (2008). Statin treatment in hypercholesterolemic pregnant mice reduces cardiovascular risk factors in their offspring. Hypertension 51: 939–944.
Freeman MR, Solomon KR . (2004). Cholesterol and prostate cancer. J Cell Biochem 91: 54–69.
Gajate C, Del Canto-Janez E, Acuna AU, Amat-Guerri F, Geijo E, Santos-Beneit AM et al. (2004). Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med 200: 353–365.
Gajate C, Fonteriz RI, Cabaner C, Alvarez-Noves G, Alvarez-Rodriguez Y, Modolell M et al. (2000a). Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer 85: 674–682.
Gajate C, Gonzalez-Camacho F, Mollinedo F . (2009a). Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS ONE 4: e5044.
Gajate C, Gonzalez-Camacho F, Mollinedo F . (2009b). Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem Biophys Res Commun 380: 780–784.
Gajate C, Mollinedo F . (2001). The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98: 3860–3863.
Gajate C, Mollinedo F . (2002). Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab 3: 491–525.
Gajate C, Mollinedo F . (2005). Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem 280: 11641–11647.
Gajate C, Mollinedo F . (2007). Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109: 711–719.
Gajate C, Santos-Beneit AM, Macho A, Lazaro M, Hernandez-De Rojas A, Modolell M et al. (2000b). Involvement of mitochondria and caspase-3 in ET-18-OCH3-induced apoptosis of human leukemic cells. Int J Cancer 86: 208–218.
Grassme H, Cremesti A, Kolesnick R, Gulbins E . (2003). Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 22: 5457–5470.
Hanson PK, Malone L, Birchmore JL, Nichols JW . (2003). Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. J Biol Chem 278: 36041–36050.
Harder T, Scheiffele P, Verkade P, Simons K . (1998). Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol 141: 929–942.
Hope HR, Pike LJ . (1996). Phosphoinositides and phosphoinositide-utilizing enzymes in detergent-insoluble lipid domains. Mol Biol Cell 7: 843–851.
Hussein MA, Juturi JV, Lieberman I . (2002). Multiple myeloma: present and future. Curr Opin Oncol 14: 31–35.
Jasinska M, Owczarek J, Orszulak-Michalak D . (2007). Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 59: 483–499.
Karasavvas N, Erukulla RK, Bittman R, Lockshin R, Zakeri Z . (1996). Stereospecific induction of apoptosis in U937 cells by N-octanoyl-sphingosine stereoisomers and N-octyl-sphingosine. The ceramide amide group is not required for apoptosis. Eur J Biochem 236: 729–737.
Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M . (1990). Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1045: 115–120.
Kolanjiappan K, Ramachandran CR, Manoharan S . (2003). Biochemical changes in tumor tissues of oral cancer patients. Clin Biochem 36: 61–65.
Li YC, Park MJ, Ye SK, Kim CW, Kim YN . (2006). Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 168: 1107–1118; quiz 1404-1105.
Megha, London E . (2004). Ceramide selectively displaces cholesterol from ordered lipid domains (rafts): implications for lipid raft structure and function. J Biol Chem 279: 9997–10004.
Mihelic R, Kaufman JL, Lonial S . (2007). Maintenance therapy in multiple myeloma. Leukemia 21: 1150–1157.
Mollinedo F . (2007). Antitumor ether lipids: proapoptotic agents with multiple therapeutic indications. Expert Opin Ther Pat 17: 385–405.
Mollinedo F . (2008). Myeloma Therapy. Pursuing The Plasma Cell. Lonial S (ed). Humana Press: Totowa, NJ, pp Chapter 25, pp. 393–419.
Mollinedo F, Fernandez-Luna JL, Gajate C, Martin-Martin B, Benito A, Martinez-Dalmau R et al. (1997). Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-XL . Cancer Res 57: 1320–1328.
Mollinedo F, Gajate C . (2006a). Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat 9: 51–73.
Mollinedo F, Gajate C . (2006b). Fas Signaling. Wajant H (ed). Landes Bioscience and Springer Science: Georgetown, TX, pp Chapter 2, pp 13–27.
Mollinedo F, Gajate C, Martin-Santamaria S, Gago F . (2004). ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem 11: 3163–3184.
Mollinedo F, Gajate C, Morales AI, del Canto-Janez E, Justies N, Collia F et al. (2009). Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J Pharmacol Exp Ther 329: 439–449.
Nieto-Miguel T, Gajate C, Mollinedo F . (2006). Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells. J Biol Chem 281: 14833–14840.
Nybond S, Bjorkqvist YJ, Ramstedt B, Slotte JP . (2005). Acyl chain length affects ceramide action on sterol/sphingomyelin-rich domains. Biochim Biophys Acta 1718: 61–66.
Perez-Sala D, Collado-Escobar D, Mollinedo F . (1995). Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease. J Biol Chem 270: 6235–6242.
Perez-Sala D, Mollinedo F . (1994). Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 199: 1209–1215.
Quesada E, Delgado J, Gajate C, Mollinedo F, Acuna AU, Amat-Guerri F . (2004). Fluorescent phenylpolyene analogues of the ether phospholipid edelfosine for the selective labeling of cancer cells. J Med Chem 47: 5333–5335.
Rouquette-Jazdanian AK, Pelassy C, Breittmayer JP, Aussel C . (2007). Full CD3/TCR activation through cholesterol-depleted lipid rafts. Cell Signal 19: 1404–1418.
Schon A, Freire E . (1989). Thermodynamics of intersubunit interactions in cholera toxin upon binding to the oligosaccharide portion of its cell surface receptor, ganglioside GM1. Biochemistry 28: 5019–5024.
Simons K, Toomre D . (2000). Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1: 31–39.
Tosi MR, Tugnoli V . (2005). Cholesteryl esters in malignancy. Clin Chim Acta 359: 27–45.
Zerp SF, Vink SR, Ruiter GA, Koolwijk P, Peters E, van der Luit AH et al. (2008). Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents. Anticancer Drugs 19: 65–75.
Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR . (2005). Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115: 959–968.
Acknowledgements
This work was supported by grants from Ministerio de Ciencia e Innovación (SAF2007-61261, SAF2008-02251, PCT-090100-2007-27, RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III), Fondo de Investigación Sanitaria and European Commission (FIS-FEDER 06/0813, PS09/01915), Junta de Castilla y León (GR15-Experimental Therapeutics and Translational Oncology Program, and Biomedicine Project 2009) and Caja Navarra Foundation, Department of Health of the Navarra Government (‘Ortiz de Landázuri, 2009’ project). CG is supported by the Ramón y Cajal Program from the Ministerio de Ciencia e Innovación of Spain. AEHdM is supported by a research grant (BF106.37) from the Department of Education of the Basque Government.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Mollinedo, F., de la Iglesia-Vicente, J., Gajate, C. et al. Lipid raft-targeted therapy in multiple myeloma. Oncogene 29, 3748–3757 (2010). https://doi.org/10.1038/onc.2010.131
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.131
- Springer Nature Limited
Keywords
This article is cited by
-
Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts
Leukemia (2018)
-
Membrane perturbation through novel cell-penetrating peptides influences intracellular accumulation of imatinib mesylate in CML cells
Cell Biology and Toxicology (2018)
-
Inositol-C2-PAF acts as a biological response modifier and antagonizes cancer-relevant processes in mammary carcinoma cells
Cellular Oncology (2018)
-
Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding
Scientific Reports (2016)
-
The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway
Tumor Biology (2016)